{"disease":{"id":"raynaud-phenomenon-secondary-to-systemic-sclerosis","name":"raynaud phenomenon secondary to systemic sclerosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04040322","title":"Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Civi Biopharma, Inc.","has_results":true},{"nct_id":"NCT03717961","title":"Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03867097","title":"Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Civi Biopharma, Inc.","has_results":true},{"nct_id":"NCT04915950","title":"A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Pfizer","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}